Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC monthly Stock Chart
AZN [NASD]
AstraZeneca PLC
Index- P/E56.33 EPS (ttm)0.95 Insider Own0.50% Shs Outstand2.62B Perf Week-2.53%
Market Cap137.05B Forward P/E21.23 EPS next Y2.52 Insider Trans0.00% Shs Float2.60B Perf Month0.94%
Income2.50B PEG2.93 EPS next Q0.64 Inst Own16.90% Short Float0.23% Perf Quarter-6.02%
Sales25.87B P/S5.30 EPS this Y-39.70% Inst Trans-4.61% Short Ratio1.29 Perf Half Y0.13%
Book/sh4.65 P/B11.52 EPS next Y26.15% ROA4.10% Target Price59.73 Perf Year9.84%
Cash/sh3.30 P/C16.23 EPS next 5Y19.20% ROE20.70% 52W Range36.15 - 64.94 Perf YTD7.44%
Dividend1.40 P/FCF- EPS past 5Y1.00% ROI8.30% 52W High-18.87% Beta0.61
Dividend %2.61% Quick Ratio0.80 Sales past 5Y-1.70% Gross Margin80.10% 52W Low45.74% ATR1.35
Employees70600 Current Ratio1.00 Sales Q/Q2.70% Oper. Margin16.40% RSI (14)42.88 Volatility1.81% 1.77%
OptionableYes Debt/Eq1.83 EPS Q/Q116.60% Profit Margin9.70% Rel Volume2.58 Prev Close53.57
ShortableYes LT Debt/Eq1.54 EarningsNov 05 BMO Payout147.40% Avg Volume4.69M Price52.69
Recom1.60 SMA20-2.97% SMA50-2.73% SMA2000.98% Volume3,433,606 Change-1.65%
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Nov-25-20 10:16AM  
07:49AM  
07:43AM  
07:00AM  
06:55AM  
06:00AM  
Nov-24-20 05:12PM  
02:39PM  
01:39PM  
01:36PM  
01:30PM  
01:20PM  
12:10PM  
12:05PM  
11:45AM  
11:27AM  
10:53AM  
10:32AM  
10:30AM  
09:21AM  
08:12AM  
08:10AM  
07:57AM  
07:50AM  
07:40AM  
06:57AM  
06:37AM  
04:52AM  
04:32AM  
03:43AM  
02:00AM  
01:03AM  
12:44AM  
Nov-23-20 08:10PM  
07:25PM  
06:05PM  
06:00PM  
05:42PM  
05:40PM  
05:24PM  
05:00PM  
04:53PM  
04:42PM  
04:13PM  
04:08PM  
03:26PM  
02:26PM  
02:21PM  
02:11PM  
02:10PM  
02:02PM  
01:56PM  
01:38PM  
01:17PM  
12:56PM  
12:49PM  
12:15PM  
12:01PM  
11:56AM  
11:36AM  
11:12AM  
10:59AM  
10:59AM  
10:24AM  
10:20AM  
09:58AM  
09:56AM  
09:48AM  
09:47AM  
09:46AM  
09:23AM  
09:21AM  
09:10AM  
08:54AM  
08:48AM  
08:23AM  
08:13AM  
07:38AM  
06:33AM  
05:40AM  
05:13AM  
04:53AM  
04:51AM  
04:25AM  
04:14AM  
04:12AM  
04:00AM  
03:48AM  
03:43AM  
02:38AM  
02:11AM  
Nov-20-20 07:01PM  
04:15PM  
03:54PM  
11:25AM  
10:15AM  
09:46AM  
07:55AM  
07:37AM  
07:00AM  
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.